Trial reportInternational journal of clinical pharmacy2025
Impact of pharmacist-physician collaboration on patient outcomes in Parkinson's disease: a randomised controlled trial in tertiary care.
Trial report in International journal of clinical pharmacy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05410210 (A Randomized Controlled Trial to Study the Impact of Pharmaceutical Care on Drug-related Problems in Patients With Parkinson's Disease at Parkinson's Disease and Movement Disorders Clinic, Siriraj Hospital, Thailand), which is not on this map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Randomized Controlled Trial to Study the Impact of Pharmaceutical Care on Drug-related Problems in Patients With Parkinson's Disease at Parkinson's Disease and Movement Disorders Clinic, Siriraj Hospital, Thailand
Who cites it
1 citing paper in PubMed.
- Clinical prediction of sodium valproate-induced movement disorders in hospitalized patients: a nomogram-based model using real-world data.International journal of clinical pharmacy · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPrevious studies have shown that reducing drug-related problems (DRPs) may improve therapeutic outcomes in patients with Parkinson's disease (PD).
aimTo investigate the impact of pharmacist participation in Parkinson's disease clinic on the number of DRPs, clinical outcomes, and the quality of life of PD patients.
methodThis single-blinded randomised controlled trial was conducted at the Parkinson's Disease and Movement Disorders Clinic. Patients aged ≥ 18 years, diagnosed with idiopathic PD for at least 3 years, and receiving antiparkinsonian drugs were randomly assigned (1:1) to the pharmacist-physician (PP) or usual care (UC) groups. The primary outcome was changes in the number of DRPs from baseline to 24 weeks between groups. Secondary outcomes included the Movement Disorder Society-Sponsored Revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) score, eight-item version of the Parkinson's Disease Questionnaire (PDQ-8) score, and Patients' Global Impression of Change (PGIC) score at week 24.
resultsA total of 80 patients were randomised, with 40 in each group. The mean number of DRPs reduced in both groups; however, the reduction was greater in the PP group compared to the UC group (- 7.2 ± 3.6 vs. - 3.0 ± 1.8, p < 0.001), especially non-adherence issues. The MDS-UPDRS and PDQ-8 scores showed significantly greater improvement in the PP group. A higher proportion of patients in the PP group achieved improvement in PGIC scales compared to those in the UC group.
conclusionOur findings demonstrated that pharmacist-physician collaboration service in the PD clinic positively impacted patient outcomes.
trial registrationClinicalTrials.gov NCT05410210 (date 13 May 2022).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.